CD40 and systemic lupus erythematosus: A possible next step could be to label Iscalimab, a human anti-human CD40 monoclonal antibody produced by Novartis, which is currently being tested in SLE, Sjögren’s disease and Type 1 Diabetes Mellitus (Clinical trial # NCT03656562, NCT03905525, NCT04129528) [33].